Information Provided By: 
Fly News Breaks for November 12, 2019
PTCT
Nov 12, 2019 | 08:36 EDT
SunTrust analyst Robyn Karnauskas initiated coverage of PTC Therapeutics with a Buy rating and $78 price target. The analyst believes that the stock can "move a lot" if the company's launches go better than expected, noting that with two marketed products, 4 new launches in the next 12 months, and the possibility to break even in the next 2-3 years, investors are only missing "leverage" to get behind the name.
News For PTCT From the Last 2 Days
There are no results for your query PTCT
